SCHEMBL28762994

SCHEMBL28762994

N#C/C(=C\c1ccc(O)c(CO)c1)C(=O)Nc1ccc(N)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 5/20 0.59
▸ CA1 P00915 5/20 0.59
▸ CA2 P00918 5/20 0.59
▸ CA9 Q16790 5/20 0.59
▸ MAPT P10636 6/20 0.59
▸ KMT2A Q03164 6/20 0.59
▸ EGFR P00533 6/20 0.59
▸ MEN1 O00255 5/20 0.59
▸ MAPK1 P28482 5/20 0.59
▸ ALDH1A1 P00352 4/20 0.59
▸ PKM P14618 3/20 0.59
▸ ERBB2 P04626 3/20 0.59
▸ KDM4E B2RXH2 3/20 0.59
▸ LMNA P02545 3/20 0.59
▸ TP53 P04637 3/20 0.59
▸ CYP3A4 P08684 3/20 0.59
▸ HPGD P15428 3/20 0.59
▸ ALOX15 P16050 3/20 0.59
▸ ALOX12 P18054 3/20 0.59
▸ NFKB1 P19838 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28762995 1.00 CA12 (0.59) CA12CA1CA2CA9MAPT
SCHEMBL28558448 0.87 EGFR (0.77) CA12CA1CA2CA9MAPT
SCHEMBL28558447 0.87 EGFR (0.77) CA12CA1CA2CA9MAPT
SCHEMBL28553002 0.83 KLK7 (0.55) CA12CA1CA2CA9MAPT
SCHEMBL28552143 0.80 CA12 (0.73) CA12CA1CA2CA9MAPT
SCHEMBL14354772 0.79 EGFR (0.76) CA12CA1CA2CA9MAPT
SCHEMBL28912063 0.78 EGFR (0.70) MAPTKMT2AEGFRMEN1MAPK1
SCHEMBL28562106 0.78 EGFR (0.70) MAPTKMT2AEGFRMEN1MAPK1
SCHEMBL8996081 0.75 EGFR (0.77) CA12CA1CA2CA9MAPT
SCHEMBL8996038 0.75 EGFR (0.77) CA12CA1CA2CA9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114656372-B P-phenylenediamine bridging compound and application thereof in preparation of medicines for treating sugar metabolism disorder diseases 广州药本君安医药科技股份有限公司 2024-06-18 — — CN disclosed
CN-114573476-B Linear head-tail diamine bridging compound and application thereof in preparation of medicines for treating sugar metabolic disorder diseases 广州药本君安医药科技股份有限公司 2024-06-11 — — CN disclosed
CN-114656371-B 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism 广州药本君安医药科技股份有限公司 2024-03-12 — — CN disclosed
CN-114656371-A 1, 4-cyclohexanediamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases 广州药本君安医药科技股份有限公司 2022-06-24 — — CN disclosed
CN-114656372-A P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases 广州药本君安医药科技股份有限公司 2022-06-24 — — CN disclosed
CN-114573476-A Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases 广州药本君安医药科技股份有限公司 2022-06-03 — — CN disclosed
Send feedback